Accretion Nutraveda IPO was launched as a Book Built SME public issue by Accretion Nutraveda Limited. The public issue comprised entirely of a fresh issue of equity shares, enabling the company to raise funds for expanding its manufacturing capabilities, strengthening operational efficiency, and supporting future business growth. After the completion of the IPO process, the company’s equity shares were listed on the BSE SME platform.
Accretion Nutraveda Limited is engaged in the development and manufacturing of nutraceutical, Ayurvedic, herbal, and wellness products. The company offers a diversified portfolio that includes tablets, capsules, powders, syrups, oils, gummies, oral liquids, and other healthcare formulations manufactured for customers across the pharmaceutical, healthcare, and nutraceutical industries.
Its operations cover product formulation, manufacturing, packaging, quality control, and contract manufacturing services. The company focuses on maintaining quality standards, improving production efficiency, and developing products that meet the changing requirements of domestic and international customers.
India’s nutraceutical and herbal healthcare industry has experienced strong growth due to increasing health awareness, preventive healthcare practices, rising demand for dietary supplements, and greater consumer preference for herbal and wellness products. These favourable industry trends continue to create long-term growth opportunities for companies operating in this segment.
Although the IPO process has been completed and the company’s shares are listed, investors should carefully analyse the company’s financial performance, manufacturing capabilities, valuation, competitive position, and long-term growth prospects before making any investment decision.
Accretion Nutraveda IPO Details
| IPO Details | Information |
|---|---|
| IPO Name | Accretion Nutraveda IPO |
| Company Name | Accretion Nutraveda Limited |
| IPO Type | Book Built Issue |
| IPO Category | SME IPO |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹122 to ₹129 Per Share |
| Issue Size | ₹24.77 Crore |
| Fresh Issue | ₹24.77 Crore |
| Offer for Sale | Nil |
| Fresh Issue Shares | 19,20,000 Equity Shares |
| IPO Open Date | 28 January 2026 |
| IPO Close Date | 30 January 2026 |
| Basis of Allotment | 2 February 2026 |
| Refund Initiation | 3 February 2026 |
| Shares Credited to Demat Account | 3 February 2026 |
| Listing Date | 4 February 2026 |
| Listing Exchange | BSE SME |
| Lot Size | 1,000 Equity Shares |
| Registrar | KFin Technologies Limited |
| Book Running Lead Manager | Sobhagya Capital Options Private Limited |
The IPO consisted solely of a fresh issue of equity shares. The company intends to utilise the net proceeds to establish a new manufacturing facility, upgrade and automate its existing production unit, meet working capital requirements, and support general corporate purposes.
Accretion Nutraveda IPO Dates
The important dates relating to the Accretion Nutraveda IPO are provided below.
| IPO Event | Date |
|---|---|
| IPO Opening Date | 28 January 2026 |
| IPO Closing Date | 30 January 2026 |
| Basis of Allotment | 2 February 2026 |
| Refund Initiation | 3 February 2026 |
| Shares Credited to Demat Account | 3 February 2026 |
| Listing Date | 4 February 2026 |
Following the completion of the allotment process, successful applicants received the allotted equity shares in their demat accounts before trading commenced on the BSE SME platform.
Accretion Nutraveda IPO Reservation
| Investor Category | Reservation |
|---|---|
| Qualified Institutional Buyers (QIB) | Not More Than 50% |
| Non-Institutional Investors (NII) | Not Less Than 15% |
| Retail Individual Investors (RII) | Not Less Than 35% |
The allocation of shares among eligible investor categories was carried out in accordance with the applicable regulatory framework governing SME Book Built public issues. The final allotment in each category depended on the number of valid applications received during the subscription period.
Accretion Nutraveda IPO Lot Size
| Application Category | Lots | Shares | Investment |
|---|---|---|---|
| Retail (Minimum) | 2 | 2,000 | ₹258,000 |
| Retail (Maximum) | 2 | 2,000 | ₹258,000 |
| S-HNI (Minimum) | 3 | 3,000 | ₹387,000 |
| B-HNI (Minimum) | 8 | 8,000 | ₹1,032,000 |
Applications were accepted only in the prescribed lot size and its multiples. The investment amounts shown above are calculated using the upper price band of ₹129 per equity share.
About Accretion Nutraveda Limited
Accretion Nutraveda Limited is engaged in the contract manufacturing and development of nutraceutical, Ayurvedic, herbal, and wellness products. The company manufactures a wide variety of healthcare formulations for brand owners, marketers, and healthcare companies, offering end-to-end manufacturing solutions from product development to final packaging.
Its manufacturing portfolio includes tablets, capsules, powders, oral liquids, syrups, gummies, soft gels, oils, and other nutritional formulations. By offering customised manufacturing services and maintaining stringent quality standards, the company caters to the evolving requirements of customers in the healthcare and wellness industry.
The company places significant emphasis on research, product formulation, quality assurance, and regulatory compliance. Its manufacturing facilities are designed to produce multiple dosage forms while maintaining consistency, product safety, and manufacturing efficiency.
Driven by increasing consumer awareness regarding preventive healthcare and nutritional wellness, Accretion Nutraveda Limited continues to expand its manufacturing capabilities and product offerings to strengthen its position in India’s growing nutraceutical industry.
Business Operations
Accretion Nutraveda Limited provides contract manufacturing and product development services for nutraceutical and Ayurvedic healthcare products. The company supports customers throughout the manufacturing cycle, from formulation development to packaging and dispatch.
Its principal business activities include:
- Contract manufacturing of nutraceutical products.
- Manufacturing of Ayurvedic formulations.
- Production of herbal healthcare products.
- Development of dietary supplements.
- Manufacturing of tablets, capsules, powders, syrups, and oral liquids.
- Production of gummies and wellness formulations.
- Product formulation and research support.
- Packaging and private label manufacturing.
- Quality assurance and regulatory compliance.
- Manufacturing for domestic and export markets.
The company’s integrated manufacturing model enables it to offer customised solutions while maintaining product quality, operational efficiency, and timely deliveries.
Product Portfolio
Accretion Nutraveda Limited manufactures a diversified range of healthcare and wellness products for different customer segments.
Its major product categories include:
- Nutraceutical Tablets
- Nutraceutical Capsules
- Protein Powders
- Herbal Powders
- Ayurvedic Syrups
- Oral Liquids
- Gummies
- Soft Gel Capsules
- Herbal Oils
- Dietary Supplements
- Immunity Support Products
- Sports Nutrition Products
- Women’s Health Supplements
- Children’s Nutrition Products
- Private Label Healthcare Products
The diversified portfolio enables the company to serve customers across the pharmaceutical, nutraceutical, wellness, and healthcare sectors while reducing dependence on any single product category.
Industry Overview
India’s nutraceutical industry has witnessed strong growth over the past few years, supported by increasing health awareness, preventive healthcare practices, changing lifestyles, and rising demand for nutritional supplements. Consumers are increasingly incorporating vitamins, minerals, herbal products, protein supplements, and functional foods into their daily routines to support overall health and wellness.
The growing popularity of Ayurveda, herbal healthcare products, sports nutrition, and immunity-boosting supplements has further expanded the market for nutraceutical manufacturers. Rising disposable income, expanding healthcare infrastructure, and wider product availability through pharmacies, retail outlets, and online platforms have also contributed to industry growth.
India has emerged as an important manufacturing destination for nutraceutical products due to its established pharmaceutical ecosystem, skilled workforce, and availability of herbal raw materials. As demand continues to increase in both domestic and international markets, contract manufacturers are expected to benefit from expanding outsourcing opportunities.
Supported by favourable industry trends and increasing consumer preference for preventive healthcare, the nutraceutical manufacturing sector is expected to continue its long-term growth trajectory.
Business Strategy
Accretion Nutraveda Limited aims to strengthen its position by expanding manufacturing capacity, increasing product offerings, and improving operational efficiency.
The company plans to enhance its production infrastructure through capacity expansion and automation while introducing additional product categories to meet changing customer requirements. It also intends to strengthen research and development capabilities to support new product development and customised formulations.
Another important strategic objective is to expand its customer base across domestic and international markets by building long-term relationships with healthcare brands, pharmaceutical companies, and wellness businesses.
Going forward, Accretion Nutraveda Limited intends to leverage the growing demand for nutraceutical and Ayurvedic products by enhancing manufacturing capabilities, maintaining high quality standards, and delivering innovative healthcare solutions to customers across multiple markets.
Accretion Nutraveda IPO Financial Information
A company’s financial performance is one of the key factors investors consider before applying for an IPO. Reviewing revenue growth, profitability, net worth, borrowings, and financial ratios helps in understanding the company’s operational efficiency, financial stability, and long-term growth potential.
Accretion Nutraveda Financial Summary
| Particulars | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue from Operations | ₹33.92 Crore | ₹44.81 Crore | ₹61.78 Crore |
| Total Income | ₹34.16 Crore | ₹45.13 Crore | ₹62.04 Crore |
| EBITDA | ₹5.21 Crore | ₹7.14 Crore | ₹10.46 Crore |
| Profit Before Tax (PBT) | ₹3.69 Crore | ₹5.18 Crore | ₹7.92 Crore |
| Profit After Tax (PAT) | ₹2.73 Crore | ₹3.86 Crore | ₹5.89 Crore |
| Net Worth | ₹10.54 Crore | ₹14.41 Crore | ₹20.28 Crore |
| Total Borrowings | ₹5.84 Crore | ₹6.43 Crore | ₹7.08 Crore |
The company has recorded steady growth in revenue and profitability over the last three financial years. Higher operating income, improving earnings, and an increase in net worth indicate business expansion and strengthening financial performance. Borrowings have remained at manageable levels while supporting operational growth.
Accretion Nutraveda IPO Key Performance Indicators (KPIs)
| KPI | Value |
|---|---|
| Return on Equity (ROE) | 29.04% |
| Return on Capital Employed (ROCE) | 32.48% |
| Return on Net Worth (RONW) | 29.05% |
| EBITDA Margin | 16.86% |
| PAT Margin | 9.49% |
| Debt-to-Equity Ratio | 0.35 |
| Earnings Per Share (EPS) | ₹8.10 |
| Net Asset Value (NAV) Per Share | ₹27.88 |
| Price to Earnings (P/E) | 15.93x |
The company’s financial ratios indicate healthy profitability, efficient utilisation of capital, and a balanced capital structure. Investors should evaluate these indicators together with the company’s business model, valuation, industry outlook, and future expansion plans before making an investment decision.
Objects of the Accretion Nutraveda IPO
The company proposes to utilise the net proceeds from the fresh issue for the following purposes:
- Setting up a new manufacturing facility.
- Modernisation and automation of the existing manufacturing unit.
- Meeting working capital requirements.
- Funding general corporate purposes.
The proposed utilisation of the IPO proceeds is expected to enhance manufacturing capacity, improve operational efficiency, support business expansion, and strengthen the company’s financial position for future growth.
Accretion Nutraveda IPO Listing Performance
The listing performance of an IPO reflects the market’s initial response when the company’s shares begin trading on the stock exchange. While a strong listing may indicate healthy investor sentiment, investment decisions should be based on the company’s business fundamentals, financial performance, valuation, and long-term growth prospects rather than listing-day movements alone.
Accretion Nutraveda IPO Listing Details
| Particular | Value |
|---|---|
| Listing Exchange | BSE SME |
| Listing Date | 4 February 2026 |
| Issue Price | ₹129 Per Share |
| Listing Price | ₹154.80 Per Share |
| Listing Gain | 20.00% |
| Closing Price on Listing Day | ₹161.20 Per Share |
Accretion Nutraveda Limited debuted on the BSE SME platform at a premium over its issue price, reflecting positive investor participation during the listing. However, investors should evaluate the company’s operational performance and long-term business outlook instead of relying only on listing gains.
Accretion Nutraveda IPO Subscription Status
The subscription figures indicate the level of demand received from various investor categories during the IPO bidding period. Strong subscription generally reflects positive market interest, although investors should also analyse the company’s financial position, industry outlook, and valuation before investing.
Accretion Nutraveda IPO Subscription
| Investor Category | Subscription |
|---|---|
| Qualified Institutional Buyers (QIB) | 62.84 Times |
| Non-Institutional Investors (NII) | 148.37 Times |
| Retail Individual Investors (RII) | 96.41 Times |
| Total Subscription | 94.82 Times |
The IPO witnessed strong participation across all investor categories. Demand from institutional, non-institutional, and retail investors contributed to a healthy overall subscription during the bidding period.
Accretion Nutraveda IPO Review
Accretion Nutraveda Limited operates in the nutraceutical and Ayurvedic manufacturing industry by offering contract manufacturing and product development services for a broad range of healthcare and wellness products. Its diversified product portfolio includes tablets, capsules, powders, syrups, oral liquids, gummies, soft gels, and herbal formulations manufactured for various healthcare and wellness brands.
The company focuses on quality-controlled manufacturing, customised product development, regulatory compliance, and efficient production processes. With increasing demand for preventive healthcare products and nutritional supplements, the company is well positioned to benefit from the expanding nutraceutical industry.
The industry continues to grow due to rising health awareness, increasing consumer preference for herbal products, higher disposable income, and greater adoption of preventive healthcare solutions. These long-term trends provide favourable opportunities for manufacturers with diversified product portfolios and scalable manufacturing facilities.
However, investors should also consider factors such as competitive pressure, fluctuations in raw material costs, dependence on regulatory compliance, customer concentration, and execution risks related to future expansion before making an investment decision.
Accretion Nutraveda IPO Strengths
Accretion Nutraveda Limited has several strengths that support its long-term growth strategy.
- Diversified portfolio of nutraceutical and Ayurvedic products.
- Integrated manufacturing and product development capabilities.
- Modern manufacturing facilities with multiple dosage forms.
- Experienced management team.
- Strong focus on quality assurance and regulatory compliance.
- Long-term relationships with healthcare and wellness brands.
- Growing opportunities in the nutraceutical and preventive healthcare industry.
- Scalable business model supported by capacity expansion.
Accretion Nutraveda IPO Risk Factors
Like other nutraceutical manufacturing companies, Accretion Nutraveda Limited is exposed to several operational and industry-related risks.
- Intense competition within the nutraceutical and healthcare industry.
- Fluctuations in the prices and availability of raw materials.
- Dependence on regulatory approvals and quality compliance.
- Customer concentration may affect business performance.
- Working capital requirements are significant for manufacturing operations.
- Changes in consumer preferences may influence product demand.
- Delays in expanding manufacturing capacity could affect future growth.
- Economic slowdowns or changes in healthcare regulations may impact business performance.
Accretion Nutraveda IPO Promoters
Accretion Nutraveda Limited is promoted by experienced professionals with expertise in the nutraceutical, Ayurvedic, and healthcare manufacturing industry. The promoters have focused on expanding the company’s manufacturing capabilities, strengthening quality standards, developing new products, and building long-term customer relationships to support sustainable business growth.
Accretion Nutraveda IPO Promoters Details
| Promoter | Designation |
|---|---|
| Amit Bansal | Promoter & Managing Director |
| Neha Bansal | Promoter & Whole-Time Director |
Accretion Nutraveda IPO Management Team
The company is managed by professionals with experience in manufacturing, product development, quality assurance, finance, operations, marketing, and corporate governance. The management team is responsible for overseeing business operations, production planning, regulatory compliance, and future growth initiatives.
| Name | Designation |
|---|---|
| Amit Bansal | Managing Director |
| Neha Bansal | Whole-Time Director |
| Chief Financial Officer | CFO |
| Company Secretary & Compliance Officer | Company Secretary |
| Independent Directors | Independent Directors |
Accretion Nutraveda IPO Registrar Details
KFin Technologies Limited acted as the registrar to the issue. The registrar was responsible for processing IPO applications, finalising the basis of allotment, facilitating the credit of equity shares to successful applicants’ demat accounts, processing refunds where applicable, and handling investor-related queries associated with the public issue.
| Particular | Details |
|---|---|
| Registrar Name | KFin Technologies Limited |
| Website | www.kfintech.com |
| IPO Allotment Status | https://ris.kfintech.com/ipostatus |
| Email ID | [email protected] |
| Contact Number | +91-40-6716 2222 |
Investors may contact the registrar regarding IPO allotment status, refunds, demat credit, or other issue-related assistance.
Accretion Nutraveda IPO Lead Manager Details
Sobhagya Capital Options Private Limited served as the Book Running Lead Manager for the IPO. The lead manager coordinated the public issue, managed regulatory documentation, supervised the IPO process, and assisted the company in completing the issue in accordance with the applicable regulatory requirements.
| Particular | Details |
|---|---|
| Lead Manager | Sobhagya Capital Options Private Limited |
| Website | www.sobhagyacapital.com |
| Email ID | [email protected] |
| Contact Number | As available on the official website |
The lead manager worked closely with the company and other intermediaries to facilitate the successful completion of the IPO process.
Accretion Nutraveda Limited Contact Details
The following contact details may be used by investors, customers, suppliers, and other stakeholders for business and investor-related communication.
| Particular | Details |
|---|---|
| Company Name | Accretion Nutraveda Limited |
| Registered Office | Ahmedabad, Gujarat, India |
| Website | https://accretionnutraveda.com/ |
| Email ID | [email protected] |
| Phone Number | As available on the company’s official website |
How to Check Accretion Nutraveda IPO Allotment Status
Applicants could check the allotment status after the basis of allotment was finalised through either the registrar’s online portal or the BSE IPO platform.
Through KFin Technologies Limited
- Visit the official IPO allotment portal of KFin Technologies Limited.
- Select Accretion Nutraveda IPO from the list of available public issues.
- Choose any one of the available search options, such as Application Number, PAN, or DP/Client ID.
- Enter the required details in the respective field.
- Click the submit button to view the allotment status.
Through BSE
- Visit the official BSE IPO allotment portal.
- Select Accretion Nutraveda IPO from the list of available IPOs.
- Enter your PAN, Application Number, or DP/Client ID.
- Complete the verification process, if required.
- Click on the search button to check your allotment status.
Frequently Asked Questions (FAQs)
What is Accretion Nutraveda IPO?
Accretion Nutraveda IPO is a Book Built SME public issue comprising only a fresh issue of equity shares.
What was the price band of the Accretion Nutraveda IPO?
The IPO was offered at a price band of ₹122 to ₹129 per equity share.
What was the total issue size of the Accretion Nutraveda IPO?
The total issue size of the IPO was ₹24.77 crore.
When did the Accretion Nutraveda IPO open and close?
The IPO opened on 28 January 2026 and closed on 30 January 2026.
On which stock exchange are Accretion Nutraveda shares listed?
The company’s equity shares are listed on the BSE SME platform.
Who was the registrar for the Accretion Nutraveda IPO?
KFin Technologies Limited was appointed as the registrar to the issue.
Who was the lead manager for the Accretion Nutraveda IPO?
Sobhagya Capital Options Private Limited acted as the Book Running Lead Manager for the IPO.
What was the minimum lot size for the Accretion Nutraveda IPO?
Retail investors were required to apply for a minimum of 2 lots comprising 2,000 equity shares.
What does Accretion Nutraveda Limited do?
Accretion Nutraveda Limited manufactures nutraceutical, Ayurvedic, herbal, and wellness products and provides contract manufacturing solutions for healthcare and nutrition brands.
What were the objectives of the Accretion Nutraveda IPO?
The company plans to utilise the proceeds from the fresh issue to establish a new manufacturing facility, modernise and automate its existing manufacturing unit, meet working capital requirements, and support general corporate purposes.
